Experimental and Developmental Therapeutics

The Experimental and Developmental Therapeutics (EDT) program is focused on improving the treatments for cancer. The activities within this program span the range of experimental and developmental therapeutics from initial target discovery to regulatory approval for new treatments. The EDT program facilitates the assessment of novel therapies by fostering collaboration between pre-clinical and clinical researchers to ultimately provide patients with the best possible treatments. Key themes within EDT include:

  1. identification of novel therapeutic targets,
  2. development of novel therapeutic agents and approaches and
  3. clinical evaluations of novel therapeutics to improve anticancer efficacy and quality of life.

Program development is facilitated with monthly program meetings, CTRC seminars, and program retreats. Thematic working groups within the program facilitate collaborative efforts and new opportunities in basic, translational and clinical cancer therapeutics. Interprogrammatic groups facilitate new collaborations with the researchers in the other programs of the CTRC, Cancer Development and Progression and Cancer Prevention and Population Science.

Training is a very important component of the EDT program's activities. Program members train fellows and graduate students in areas that encompass the entire spectrum of cancer therapeutics, from structural biology of new drug targets to novel clinical trial design. The IDD's Advanced Oncology/Hematology Drug Development Fellowship is a unique training program for physicians that focuses specifically on the multidisciplinary nature of anti-cancer therapy development.

In summary, the EDT program is a highly integrated multidisciplinary collaborative effort between pre-clinical and clinical scientists, all focused on providing newer, better-targeted and more effective treatments for patients with cancer.